IRIDEX Corporation IRIX

Company Overview

IRIDEX Corporation (NASDAQ: IRIX) is a U.S.-based medical technology company focused on ophthalmic devices used in the treatment of glaucoma and retinal diseases. The company develops, manufactures, and markets laser-based systems, delivery devices, and consumable instrumentation primarily for ophthalmologists and retina specialists. IRIDEX operates within the broader medical device and ophthalmology industries, with revenue primarily generated through capital equipment sales, recurring consumables, and service-related activities.

The company’s principal product families include its glaucoma treatment platform and retinal laser systems, notably the Cyclo G6 glaucoma laser platform and the IQ 532 and IQ 577 retinal laser systems. IRIDEX has positioned itself around minimally invasive and tissue-sparing laser therapies intended to improve clinical outcomes while reducing complications associated with conventional glaucoma surgery. Founded in 1989 and headquartered in Mountain View, California, IRIDEX evolved from a laser technology developer into a specialized ophthalmic therapeutics company through internal product development, clinical commercialization, and expansion into international ophthalmology markets.